PACS Group, Inc. (PACS) Stock Price & Analysis
PACS Group, Inc. (PACS) closed at USD 47.5 on Thursday, October 22, 2026, up 1.58% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 46.76; the Oct 22, 2026 session ranged USD 46–47.71 on volume of 666,971 shares. Market capitalization is $7.52B, with a 52-week range of USD 10.31–49.49 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 10:37 UTC.
Also available as compact Markdown for AI agents: nexqual.com/PACS.md
Key facts (PACS)
- Last four reported quarters (through Jun 30, 2026): revenue $5.55B, net income $269M (4.8% margin) (SEC filings).
- Valuation: P/E 27.9x (avg 33.1x at the last 2 fiscal year-ends), net debt $81.6M.
- Analysts: Buy (mean 1.67 on a 1–5 scale) (6 analysts), mean target USD 59 (range 57–62).
- Total return with dividends: 1Y +272.8% vs S&P 500 +14.9%; 5Y +97.9% vs S&P 500 +80.3%.
- Next earnings: 2026-11-09, EPS estimate USD 0.58, revenue estimate $1.46B.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (PACS)
| USD | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $2.42B | $3.11B | $4.09B | $5.29B | $5.55B |
| Operating income | $229M | $208M | $123M | $310M | $410M |
| Net income | $150M | $113M | $55.8M | $192M | $269M |
| EPS (diluted) | $1.17 | $0.88 | $0.38 | $1.22 | — |
| Operating margin | 9.5% | 6.7% | 3.0% | 5.9% | 7.4% |
| Net margin | 6.2% | 3.6% | 1.4% | 3.6% | 4.8% |
| Revenue growth | — | +28.5% | +31.4% | +29.3% | — |
| Cash + short-term investments | $58.3M | $73.4M | $158M | $197M | — |
| Total debt | — | $213M | $412M | $353M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (PACS)
P/E 27.9x · P/S 1.4x · EV/Sales 1.4x · P/B 6.8x · Earnings yield 3.58% · Net debt $81.6M · EV $7.60B
P/E at fiscal year-ends: Dec 2025 31.4x, Dec 2024 34.9x.
Analysts (PACS)
Consensus Buy (mean 1.67 on a 1–5 scale), 6 analysts; mean target USD 59 (low 57, high 62).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-04 | JP Morgan | Target raised | Overweight | $47 → $58 |
| 2026-08-10 | Oppenheimer | Target raised | Outperform | $48 → $57 |
| 2026-08-06 | UBS | Target raised | Buy | $57 → $60 |
| 2026-08-06 | RBC Capital | Target raised | Outperform | $52 → $57 |
| 2026-08-06 | Truist Securities | Target raised | Buy | $52 → $62 |
| 2026-07-08 | UBS | Target raised | Buy | $50 → $57 |
Total return (dividends reinvested) (PACS)
| 1Y (from 2025-10-23) | 5Y (from 2024-04-08) | |
|---|---|---|
| Total return | +272.8% | +97.9% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +274.5% | +30.8% |
| Volatility (annualized) | 81.3% | 89.5% |
| Max drawdown | -27.9% (Jan 2026→Mar 2026) | -78.7% (Oct 2024→Apr 2025) |
PACS customer concentration
In the period ended Jun 30, 2026, 3 direct customers each accounted for at least 10% (39.3%, 34.2%, 19.8%) of revenue, per the company's 10-Q filed Aug 4, 2026. The company does not name them.
PACS analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.58 | $0.55 | +6.6% | $1.46B | 5 |
| Next quarter (ends Dec 2026) | $0.63 | $0.57 | +9.7% | $1.54B | 5 |
| Current fiscal year (ends Dec 2026) | $2.50 | $2.32 | +7.8% | $5.85B | 5 |
| Next fiscal year (ends Dec 2027) | $2.74 | $2.45 | +11.9% | $6.54B | 5 |
Key Statistics (as of October 23, 2026 at 10:37 UTC)
| Price | USD 47.5 |
|---|---|
| Change | ▲ 1.58% (up) |
| Previous Close | USD 46.76 |
| Open | USD 46.62 |
| Day Range | USD 46 – 47.71 |
| 52-Week Range | USD 10.31 – 49.49 |
| Volume | 666,971 shares |
| Market Cap | $7.52B |
| Exchange | NYQ |
Technical Analysis (PACS)
Nexqual's technical model rates PACS "BUY" based on 5 bullish and 1 bearish signals across 127 daily candles, as of October 23, 2026 at 10:37 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 63.59 (neutral) |
| vs SMA50 | Above (USD 43.68) |
| MACD | 1.14 (positive) |
Analyst Ratings (PACS)
Wall Street analysts rate PACS "Buy" based on 6 analysts, with a mean price target of USD 59 (range USD 57–62), per Nexqual as of October 23, 2026 at 10:37 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 59 |
| High Target | USD 62 |
| Low Target | USD 57 |
| Buy / Hold / Sell | 6 / 0 / 0 |
Earnings (PACS)
| Next Earnings Date | 2026-11-09 |
|---|---|
| EPS Estimate | USD 0.58 |
| Revenue Estimate | $1.46B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.63 vs est 0.56 ▲ beat |
| 2026-03-31 | USD 0.64 vs est 0.41 ▲ beat |
| 2025-12-31 | USD 0.57 vs est 0.46 ▲ beat |
| 2025-09-30 | USD 0.45 vs est 0.47 ▼ miss |
Source: Nexqual, October 23, 2026 at 10:37 UTC.
Financials & Fundamentals (PACS)
| Total Revenue | $5.55B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +9.10% |
| Gross Margin | +17.32% |
| Operating Margin | +7.66% |
| Profit Margin | +4.85% |
| ROE | +27.92% |
| Debt / Equity | 3.05 |
| Current Ratio | 0.91 |
| Total Cash | $164.45M |
| Total Debt | $3.40B |
Source: Nexqual, October 23, 2026 at 10:37 UTC.
Financial Health Score (PACS)
Nexqual rates PACS Group, Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 10:37 UTC.
| Growth | Strong — Revenue +29% YoY (annual) |
|---|---|
| Profitability | Mixed — Gross margin 17%, operating 8% (last 12 months) |
| Balance Sheet | Critical — $164M cash and investments vs $246M debt (Jun 2026, SEC) |
| Cash Flow | Solid — Operating cash flow $404M (FY ended Dec 2025, 10-K) |
| Efficiency | Strong — ROE 28%, ROA 4.6% |
Ownership (PACS)
| Insider Ownership | +68.89% |
|---|---|
| Institutional Ownership | +31.73% |
| Shares Outstanding | 158.34M |
| Float | 49.12M |
| Short % of Float | +8.56% |
Source: Nexqual, October 23, 2026 at 10:37 UTC.
Leadership (PACS)
PACS Group, Inc. is led by Jason Murray, Co-Founder, CEO & Chairman, per Nexqual as of October 23, 2026 at 10:37 UTC.
| Co-Founder, CEO & Chairman | Jason Murray |
|---|---|
| Co-Founder & Vice Chairman | Mark Hancock |
| President & COO | Joshua Jergensen |
| Chief Financial Officer | Carey P. Hendrickson |
| Director of Corporate Finance | Ryan Welch |
Major Backers & Investors (PACS)
Notable institutional backers of PACS Group, Inc. include Cohen & Steers Inc., FMR, LLC, Crewe Advisors LLC, according to Nexqual as of October 23, 2026 at 10:37 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Cohen & Steers Inc. | 5.27% |
| FMR, LLC | 3.92% |
| Crewe Advisors LLC | 2.09% |
| American Century Companies Inc | 1.96% |
| Fidelity | 1.78% |
| Ameriprise Financial, Inc. | 1.26% |
| Alyeska Investment Group, L.p. | 0.97% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 2.63% |
| Vanguard Group | 2.41% |
| Dimensional Fund Advisors | 0.78% |
Source: Nexqual, October 23, 2026 at 10:37 UTC.
From PACS Group, Inc.'s Latest SEC 10-K Filing (filed 2026-02-27)
Key Strengths & Strategy (as disclosed to the SEC)
- PACS Services includes access to an industry-leading, third-party Electronic Health Record system, and a singular Enterprise Resource Program.
- Founded in 2013, we are one of the largest skilled nursing providers in the United States based on number of facilities.
- We developed PACS Services to be a resource to help reduce administrative burden so that local leadership teams can focus on making decisions that improve the care, well-being, and quality of life of their patients.
- We developed PACS Services to reduce the managerial and operational burden on our administrators, enabling them to focus on leading their facilities and spending more time with patients and staff.
Legal & Regulatory Risks (Item 1A, quoted)
- We are subject to various government and third-party payor reviews, audits and investigations that could adversely affect our business, including an obligation to refund amounts previously paid to us, potential criminal charges, the imposition of fines, and/or the loss of our right to participate in Medicare and Medicaid programs or other third-party payor programs.
- Regulators and third-party payors are increasing scrutiny of claims, which may require additional resources to response to audits and may cause additional delays or denials in receiving payment.
- We are subject to extensive and complex laws and government regulations. If we are not operating in compliance with these laws and regulations or if these laws and regulations change, we could be required to make significant expenditures or change our operations in order to bring our facilities and operations into compliance.
- We face and are currently subject to surveys, investigations, and other proceedings relating to our licenses and certification and potential sanctions and remedies based upon alleged regulatory deficiencies could negatively affect our financial condition and results of operations.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CHE | Chemed Corp | USD 520.15 | ▲ 1.72% |
| ENSG | The Ensign Group, Inc. | USD 178.35 | ▲ 2.88% |
| UHS | Universal Health Services, Inc. | USD 188.13 | ▲ 2.88% |
| CON | Concentra Group Holdings Parent | USD 39.97 | ▲ 2.25% |
| DVA | DaVita Inc. | USD 186.1 | ▲ 5.25% |
| OPCH | Option Care Health, Inc. | USD 31.29 | ▼ 0% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 10:37 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt